This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
NOI - Whole Genome Sequencing-Sickle Cell Patient
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health, Office of the Director, Office of Acquisitions, intends to award a firm-fixed-price purchase order without full and open competition to The Broad Institute, Inc. for whole genome sequencing services under the authority of FAR Part 12.603 and 41 U.S.C. 1901, citing FAR 6.302-3(a)(2)(ii) for sole-source acquisition due to the unique and irreplaceable capability of the offeror. The requirement is for high-quality whole genome sequencing at a minimum of 60X average coverage on 250 clinical sickle cell disease patient samples, with strict adherence to established sequencing and bioinformatics protocols previously used by The Broad Institute to ensure data continuity and compatibility with existing genomic datasets. Deviation from these protocols is deemed to present unacceptable technical and programmatic risk, justifying the non-competitive nature of the acquisition. The solicitation, issued as a combined synopsis and notice of intent, does not anticipate exceeding the simplified acquisition threshold, and no set-aside provisions apply, with the NAICS code 541990 applicable to the procurement. Evaluation of proposals will prioritize methodological consistency, sequencing depth, data quality metrics including alignment and duplication rates, and completion of required quality control standards, with award based on technical superiority rather than lowest price. Performance is to occur at The Broad Institute’s facility in Cambridge, Massachusetts, with all deliverables—including raw sequencing data, processed files, and comprehensive quality control reports—received electronically at the government’s location. The period of performance is scheduled from June 1, 2026, to September 30, 2026, with an option to extend services under FAR 52.217-8 subject to availability of funds. Delivery is FOB destination, and no physical packaging or shipping requirements are specified beyond the electronic transfer of data. Invoices must be submitted electronically through the Department of Treasury’s Invoice Processing Platform, with a copy sent to NHLBIContractsBranchB@mail.nih.gov. Offerors must provide a valid UEI, TIN, and completed Standard Form 18 with representations and certifications per FAR 52.212-3, and responses must be submitted electronically to nicholas.capobianco@nih.gov no later than May 29, 2026. No attachments, military standards, barcoding, labeling, or security clearances are required, and the contract is structured as a
General Info
Agency
NAICS
Place of Performance
MDSet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
(ii) The solicitation number is (insert solicitation number) and the solicitation is issued as a Notice of Intent (NOI) of a non-competitive (notice of intent) combined synopsis solicitation to award a contract or purchase order without providing for full or open competition (including brand-name).
This acquisition is conducted under the authority of the FAR Part 12.603 Streamlined solicitation for commercial products or commercial services and is not expected to exceed the simplified acquisition threshold, and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-3(a)(2)(ii).
The National Institutes of Health, Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order without providing for full and open competition (Including brand-name) to The Broad Institute, Inc. 415 Main Street Cambridge, MA 02142 for whole genome sequencing services.
The purpose of this acquisition is to obtain high-quality whole genome sequencing (WGS) services for sickle cell disease (SCD) patient samples to support ongoing genomic research and predictive modeling efforts. The Broad Institute is uniquely positioned to perform this requirement due to its prior sequencing of this specific cohort and use of established sequencing and bioinformatics pipelines aligned with existing datasets. Use of another vendor would introduce data variability, require reprocessing or validation of prior datasets, and pose unacceptable technical and programmatic risk.
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
